Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
InsigHHT
NCT06659640Phase 2Active, not recruiting
- Sponsor
- Alnylam Pharmaceuticals
- Start
- Nov 2024
- Primary completion
- Jan 2028
- Modality
- Conjugated siRNA, Chemically Modified siRNA
- Countries
- 6
01
Overview
A Phase 2 trial of ALN-6400 in hereditary hemorrhagic telangiectasia (HHT), sponsored by Alnylam Pharmaceuticals. Started Nov 2024; status: active, not recruiting.
02
Drugs
ALN-6400
03
Conditions
hereditary hemorrhagic telangiectasia (HHT)
Beyond the preview
Go deeper on NCT06659640.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06659640.